Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway

You,Yanjie; Li,Haijun; Chen,Jiongyu; Qin,Xin; Ran,Yonggang

doi:10.3892/ol.2017.5611

Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway

Authors:
- Yanjie You
- Haijun Li
- Jiongyu Chen
- Xin Qin
- Yonggang Ran
View Affiliations

Affiliations: Pathological Examination and Research Center, Luohe Medical College, Luohe, Henan 462002, P.R. China, Department of Radiation Oncology, The Second People's Hospital of Neijiang, Neijiang, Sichuan 641000, P.R. China, Department of Laboratory, Cancer Hospital of Shantou University, Shantou, Guangdong 515041, P.R. China, Medical College, Hubei University of Arts and Science, Xiangyang, Hubei 441053, P.R. China, Department of Teaching and Training, Bethune Military Medical NCO Academy of PLA, Shijiazhuang, Hebei 050081, P.R. China
Published online on: January 18, 2017 https://doi.org/10.3892/ol.2017.5611
Pages: 1840-1846

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite improvements to radiotherapeutic strategies, resistance to adjuvant chemotherapy remains the main problem underlying the low 5‑year survival rate in patients with nasopharyngeal carcinoma (NPC). In the present study, the human NPC cell line HNE1 was exposed to gradually increasing concentrations of cisplatin (CDDP) in order to establish a drug‑resistant sub‑cell line, HNE1/CDDP. HNE1/CDDP cells exhibited multidrug resistance and a prolonged doubling time, as compared with the parent HNE1 cells. Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP‑resistant cells by inducing S‑phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B‑cell lymphoma‑2 (BCL‑2)‑associated X protein and caspase‑9 and downregulating the expression of BCL‑2. The results of the present study suggested that HNE1/CDDP cells are a stable, multidrug‑resistant NPC cell line that may serve as an important tool for research in drug resistance. In addition, the application of ZOL may hold clinical therapeutic potential for the treatment of drug resistance in NPC.

View Figures

View References

1	Ho JH: An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 4:182–198. 1978. View Article : Google Scholar : PubMed/NCBI
2	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
3	McDermott AL, Dutt SN and Watkinson JC: The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 26:82–92. 2001. View Article : Google Scholar : PubMed/NCBI
4	Feng Z, Xu S, Liu M, Zeng YX and Kang T: Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 297:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
5	Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
6	Portugal J, Bataller M and Mansilla S: Cell death pathways in response to antitumor therapy. Tumori. 95:409–421. 2009.PubMed/NCBI
7	Wang X, Masters JR, Wong YC, Lo AK and Tsao SW: Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Res. 21:403–408. 2001.PubMed/NCBI
8	Cheung HW, Jin DY, Ling MT, Wong YC, Wang Q, Tsao SW and Wang X: Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res. 65:1450–1458. 2005. View Article : Google Scholar : PubMed/NCBI
9	Shannon KM: Resistance in the land of molecular cancer therapeutics. Cancer Cell. 2:99–102. 2002. View Article : Google Scholar : PubMed/NCBI
10	Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W and Liu Z: Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem. 340:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao F, Chen L, Xiao GG, Molnár J and Wang Q: Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res. 30:3593–3598. 2010.PubMed/NCBI
12	Peng X, Li W and Tan G: Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs. 21:381–388. 2010. View Article : Google Scholar : PubMed/NCBI
13	Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012. View Article : Google Scholar : PubMed/NCBI
14	Pan Y, Zhou F, Zhang R and Claret FX: Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
15	Catanzaro D, Vianello C, Ragazzi E, Caparrotta L and Montopoli M: Cell cycle control by natural phenols in cisplatin-resistant cell lines. Nat Prod Commun. 9:1465–1468. 2014.PubMed/NCBI
16	Xie SM, Fang WY, Liu TF, Yao KT and Zhong XY: Association of ABCC2 and CDDP-resistance in two sublines resistant to CDDP derived from a human nasopharyngeal carcinoma cell line. J Oncol. 2010:9150462010. View Article : Google Scholar : PubMed/NCBI
17	You Y, Liu J, Wang Z, Zhang Y, Ran Y, Guo X, Liu H and Wang H: The enhancement of radio-sensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism. Cytotechnology. 66:17–25. 2014. View Article : Google Scholar : PubMed/NCBI
18	Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, et al: Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep. 24:233–239. 2010.PubMed/NCBI
19	Zhao M, Tominaga Y, Ohuchida K, Mizumoto K, Cui L, Kozono S, Fujita H, Maeyama R, Toma H and Tanaka M: Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci. 103:58–66. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yan LH, Wang XT, Yang J, Kong FB, Lian C, Wei WY, Luo W, Xie YB and Xiao Q: Reversal of multidrug resistance in gastric cancer cells by E2F-1 downregulation in vitro and in vivo. J Cell Biochem. 115:34–41. 2014. View Article : Google Scholar : PubMed/NCBI
21	Liu J, Yang L, Zhang J, Zhang J, Chen Y, Li K, Li Y, Li Y, Yao L and Guo G: Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer. 12:3702012. View Article : Google Scholar : PubMed/NCBI
22	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
23	Blagosklonny MV: Targeting cancer cells by exploiting their resistance. Trends Mol Med. 9:307–312. 2003. View Article : Google Scholar : PubMed/NCBI
24	Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
25	Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, et al: Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): Pivotal role of the prenylation process. Cancer Res. 70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
26	Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, Cho R, Nishimura M and Saito Y: Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol. 79:382–391. 2007. View Article : Google Scholar : PubMed/NCBI
27	Li XY, Lin YC, Huang WL, Lin W, Wang HB, Lin WZ and Lin SL: Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway. Med Oncol. 29:3374–3380. 2012. View Article : Google Scholar : PubMed/NCBI
28	Okuno S, Shimizu S, Ito T, Nomura M, Hamada E, Tsujimoto Y and Matsuda H: Bcl-2 prevents caspase-independent cell death. J Biol Chem. 273:34272–34277. 1998. View Article : Google Scholar : PubMed/NCBI
29	Han T, Zhu X, Wang J, Zhao H, Ma Q, Zhao J, Qiu X and Fan Q: Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. Oncol Rep. 32:1133–1139. 2014.PubMed/NCBI